Previous 10 | Next 10 |
Safety and tolerability data for Cohort 2 of the Discover Study reviewed by Data Safety Monitoring Board, allowing the study to proceed with the final cohort Berwyn, Pennsylvania--(Newsfile Corp. - July 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clini...
When you're evaluating two companies that will compete for the same target market, it's a bit like betting on a boxing match. By judging what each business is capable of before the match starts, keen investors can calculate the odds and pick a profitable bet. Of course, when we're looking a...
With XPro1595, it has a disease-modifying drug candidate that has already shown to consistently decrease multiple biomarkers of neuroinflammation; The test is now how this affects biomarkers of neurodegeneration and AD; readout to be expected in August 2021; INmune Bio is not an A...
travellinglight/iStock via Getty Images The Centers for Medicare & Medicaid Services ((CMS)) announced its plans to start a process that will allow the federal agency to review and determine whether Medicare will establish a national Medicare coverage policy for monoclonal antib...
PhonlamaiPhoto/iStock via Getty Images Several biotech companies involved in developing Alzheimer's therapies are up in morning trading after some traded sharply lower on Friday following acting FDA Commissioner Janet Woodcock call for an investigation into the controversial approval of Bioge...
travellinglight/iStock via Getty Images A short while ago, Stat News reported that the acting FDA commissioner, Janet Woodcock, has called for a federal investigation into the interactions between Biogen ([[BIIB]] -2.9%) and the regulator’s staff in the run-up to FDA approval for the c...
Shares of Annovis Bio Inc. (NYSE American:ANVS) traded today at $125.95, eclipsing its 52-week high. This new high was reached on below average trading volume as 553,000 shares traded hands, while the average 30-day volume is approximately 934,000 shares. Annovis Bio Inc. (NYSE American:...
travellinglight/iStock via Getty Images It is slightly over a month ago that Biogen won the FDA approval for its Alzheimer's disease drug Aduhelm (aducanumab). However, the company’s smaller rivals in the space have continued to outperform the broader market over the past 30-day period...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharmaceutical companies can be a great investment. Especially for investors in search of long-term growth candidates for their portfolio. A successful new drug or treatment is covered by patents for 20 years in the U.S. m...
Pgiam/iStock via Getty Images Thought the COVID worries were over? Not quite. Renewed concerns about variants of the disease weighed on airline stocks on Thursday. This included declines in shares of Spirit Airlines (SAVE), United (UAL) and Delta (DAL). Elsewhere on the transportation front, ...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...